Volume 3.19 | May 22

Pulmonary Cell News 3.19 May 22, 2014
Pulmonary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
 
TOP STORY
DA-Raf-Dependent Inhibition of the Ras-ERK Signaling Pathway in Type 2 Alveolar Epithelial Cells Controls Alveolar Formation
By analyzing the Ras-ERK signaling pathway during postnatal development of lungs, scientists have identified a critical role of DA-Raf1 – a dominant-negative antagonist for the Ras-ERK signaling pathway – in alveolar formation. [Proc Natl Acad Sci USA] Abstract | Full Article
Got Cells? Rare progenitor and immune cells ready for your research
 
PUBLICATIONS (Ranked by impact factor of the journal)
Integrated Analyses Identified the Involvement of MicroRNA-26a in Epithelial-Mesenchymal Transition during Idiopathic Pulmonary Fibrosis
Inhibition of microRNA (miR)-26a resulted in lung epithelial cells transforming into myofibroblasts in vitro and in vivo, whereas forced expression of miR-26a alleviated transforming growth factor-β1- and bleomycin-induced epithelial-mesenchymal transition in A549 cells and in mice, respectively. [Cell Death Dis] Full Article

Branching Morphogenesis of Immortalized Human Bronchial Epithelial Cells in Three-Dimensional Culture
Scientists describe a three-dimensional model system using human bronchial epithelial cells (HBECs) cultured on reconstituted basement membrane. HBECs form complex budding and branching structures on reconstituted basement membrane when co-cultured with human lung fetal fibroblasts. [Differentiation] Abstract

PM10-Stimulated Airway Epithelial Cells Activate Primary Human Dendritic Cells Independent of Uric Acid: Application of an In Vitro Model System Exposing Dendritic Cells to Airway Epithelial Cell-Conditioned Media
Researchers developed and validated a model of dendritic cell exposure to airway epithelial cell-conditioned media. After establishing the model, they explored how soluble mediators released from airway epithelial cells in response to air pollution influenced the phenotype of dendritic cells. [Respirology] Abstract

Pro-Oxidative Toxicity of Cells in Suspension Does Not Point to a Cell Cultural Artefact as an Explanation of the Increased Susceptibility of Alveolar Epithelial-Like Cells after Glucocorticoid Pretreatment
The influence of cell numbers on peroxide-(tertiary butylhydroperoxide or hydrogen peroxide) or zinc-(zinc chloride) induced oxidative stress was assessed in alveolar epithelial-like cell lines. [Toxicol In Vitro] Abstract

Human Metapneumovirus Infection Induces Significant Changes in Small Noncoding RNA Expression in Airway Epithelial Cells
Scientists analyzed the changes in small noncoding RNAs (sncRNA) profiles of airway epithelial cells in response to human metapneumovirus infection using ultrahigh-throughput sequencing. Of the cloned sncRNAs, microRNA (miRNA) was dominant in A549 cells, with the percentage of miRNA increasing in a time-dependent manner after the infection. [Mol Ther Nucleic Acids] Full Article

LUNG CANCER

Pivotal Role of MUC1 Glycosylation by Cigarette Smoke in Modulating Disruption of Airway Adherens Junctions In Vitro
Using organotypic cultures of primary human bronchial epithelial cells treated with smoke-concentrated medium, scientists have demonstrated that epithelial cadherin loss is regulated through the aberrant interaction of its adherens junction binding partner, p120-catenin, and the C-terminus of mucin-1 (MUC1). [J Pathol] Abstract

Axl-Altered MicroRNAs Regulate Tumorigenicity and Gefitinib Resistance in Lung Cancer
Researchers validate and report that microRNA (miR)-374a and miR-548b modulated by Axl have essential roles in cell cycle arrest, gefitinib-induced apoptosis, epithelial-to-mesenchymal transition, migration and tumorigenesis of gefitinib-resistant lung cancer cells in vitro and in vivo by targeting Wnt5a and CCNB1 genes, respectively. [Cell Death Dis] Full Article

Mixture Effects of Benzene, Toluene, Ethylbenzene and Xylenes (BTEX) to Lung Carcinoma Cells via a Hanging Drop Air Exposure System
A recently developed hanging drop air exposure system for toxicity studies of volatile chemicals was applied to evaluate the cell viability of lung carcinoma A549 cells after one hour and 24 hours of exposure to BTEX as individual compounds and mixtures of four or six components. [Chem Res Toxicol] Abstract

Combination of Sasa quelpaertensisi Nakai Leaf Extract and Cisplatin Suppresses the Cancer Stemness and Invasion of Human Lung Cancer Cells
Scientists investigated whether Sasa quelpaertensis leaf extracts and cisplatin, individually or in combination, would exert anti-cancer stem cell and antimetastatic effect in H1299 and A549 human lung cancer cells. [Integr Cancer Ther] Abstract

Combination of BIBW2992 and ARQ 197 Is Effective against Erlotinib-Resistant Human Lung Cancer Cells with the EGFR T790M Mutation
Researchers investigated the inhibitory effects of a combination of BIBW2992 on the human lung adenocarcinoma cell line H1975. [Oncol Rep] Abstract

Air-Liquid Interface Culture for Respiratory Research: Watch Q&A Video
 
REVIEWS
Curcumin and Lung Cancer – A Review
Recently, curcumin has been widely studied for its anticancer properties via its effects on a variety of biological pathways involved in apoptosis, tumor proliferation, chemo- and radiotherapy sensitization, tumor invasion, and metastases. The authors present an overview of the current in vitro and in vivo studies of curcumin in lung cancer. [Target Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
 
SCIENCE NEWS
COPD: First Phase III Data Show Lung Function Benefits of Tiotropium + Olodaterol Fixed-Dose Combination Go Beyond Tiotropium (Spiriva®) Alone
Boehringer Ingelheim announced the first Phase III data for the once-daily fixed-dose combination of tiotropium and olodaterol. Results from the Phase III VIVACITO™ study show that once-daily tiotropium + olodaterol FDC improved lung function of COPD patients to levels significantly above those achieved with tiotropium or olodaterol monotherapies, or with placebo. [Press release from Boehringer Ingelheim GmbH discussing research presented at the American Thoracic Society (ATS) 2014 International Congress, San Diego] Press Release

GSK Presents Positive Data from Study Evaluating Efficacy and Safety of Incruse™ Ellipta® Added to Advair® Diskus® in Patients with COPD
GlaxoSmithKline plc presented data from a late-stage clinical study. In this study the safety and efficacy of the addition of a long-acting muscarinic antagonist, umeclidinium ‘UMEC’ 62.5mcg (IncruseTM Ellipta®) and UMEC 125mcg, to the inhaled corticosteroid and long-acting beta2 agonist combination medicine, fluticasone proprionate and salmeterol ‘FSC 250/50 mcg’ (Advair® Diskus®), was evaluated in chronic obstructive pulmonary disease (COPD) patients over 12 weeks. [Press release from GlaxoSmithKline plc discussing research presented at the American Thoracic Society (ATS) 2014 International Congress, San Diego]
Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
 
INDUSTRY NEWS
Bonnie J. Addario Lung Cancer Foundation and Van Auken Private Foundation Announce the 2014 Young Innovators Team Award for Lung Cancer Research
The Bonnie J. Addario Lung Cancer Foundation, in collaboration with the Van Auken Private Foundation announced the 2014 Young Innovators Team Award, a first-of-its-kind program that will fund and support teams of young investigators to conduct novel, innovative and transdisciplinary research with a potential of high clinical impact for lung cancer patients. [The Bonnie J. Addario Lung Cancer Foundation] Press Release

Clovis Oncology Receives Breakthrough Therapy Designation for CO-1686 for the Treatment of Second-Line EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) in Patients with the T790M Mutation
Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for the Company’s investigational agent CO-1686 as monotherapy for the treatment of second-line EGFR mutant NSCLC in patients with the T790M mutation. [Clovis Oncology, Inc.] Press Release

Genprex Begins Phase II Clinical Trial for Lung Cancer
Genprex, Inc. announced that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. [Genprex, Inc.] Press Release

Bold Initiative to Transform Cancer Care Established with a $100 Million Gift
Memorial Sloan Kettering Cancer Center announced the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology. Named in honor of Marie-Josée and Henry R. Kravis and the $100 million gift from their foundation, the CMO will enable researchers to speed the translation of new discoveries into routine clinical practice and reshape the design of clinical trials. [Memorial Sloan Kettering Cancer Center] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 23rd Biennial Congress of the European Association for Cancer Research
July 5-8, 2014
Munich, Germany

Visit our events page to see a complete list of events in the pulmonary cell community.
 
JOB OPPORTUNITIES
NEW PhD Position – Role of Long Non-Coding RNAs in the Lung and During Activation of Lung Fibroblasts (University of Bath)

NEW Junior Research Group Leader Position – Cell-Derived Therapeutics in Chronic Lung Disease (Helmholtz Zentrum München)

NEW Postdoctoral Fellow – Lung Biology and Genomics (Harvard University)

NEW Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Research Fellow – Allergic Lung Inflammation (Singapore Immunology Network)

Postdoctoral Fellowship – Malignant Progression of Lung Cancer (MD Anderson Cancer Center)

Research Fellow – Pulmonary Cancer (Mayo Clinic – Rochester)

Postdoctoral Researcher – Metabolomics of Pulmonary Medicine (Karolinska Institute)

Molecular Immunologist – COPD (GlaxoSmithKline)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Research Technologist – hPSC (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Pulmonary Cell News: Archives | Events | Contact Us